METHODS OF ADMINISTERING ELAGOLIX IN ASSOCIATION WITH ARTIFICIAL REPRODUCTIVE TECHNOLOGIES
A method of administering elagolix to a patient in association with an artificial reproductive technology (ART) protocol involves orally administering 150 to 400 mg elagolix per day. In accordance with certain embodiments, the method further involves the co-administration of exogenous gonadotropins...
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English |
Published |
01.12.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A method of administering elagolix to a patient in association with an artificial reproductive technology (ART) protocol involves orally administering 150 to 400 mg elagolix per day. In accordance with certain embodiments, the method further involves the co-administration of exogenous gonadotropins (rFSH or HMG) with a subsequent ovulatory trigger. In an embodiment, the patient is administered 150 to 200 mg Elagolix PO daily or twice per day. In an embodiment, the patient is administered 150 to 200 mg Elagolix PO per day at a dosing duration of a minimum of one day and a maximum of six days. In an embodiment, the ART protocol involves administering 150 to 200 mg Elagolix PO per day based upon a patient's transvaginal ultrasound and hormone levels. |
---|---|
Bibliography: | Application Number: US202117331505 |